{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "binds",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P15692",
      "entity_text" : "VEGF-A",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ02052",
      "entity_text" : "Bevacizumab",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "Bevacizumab, a humanized monoclonal antibody that binds to VEGF-A preventing its interaction with VEGFR-2, was the first antiangiogenic agent approved in mCRC (XREF_FIG and XREF_TABLE).",
  "reading_complete" : "2020-08-08T12:39:18Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T12:34:09Z",
  "trigger" : "binds",
  "evidence" : [ "Bevacizumab, a humanized monoclonal antibody that binds to VEGF-A" ],
  "pmc_id" : "4130202",
  "score" : 0
}